RxDoctor Payments Data

Chiamaka Smith, NP

Family · Louisville, KYNPI 1174241848

Payments from drug & device makers

$1,836in general payments, 2019–2025

Across 16 payments — averaging $114.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$365
  • AbbVie$235
  • Lilly USA, LLC$227
  • Astellas Pharma US Inc$125
  • Amgen$123
  • Idorsia Pharmaceuticals US Inc$120
  • plus $642 from 6 others

What the payments were for

  • Food & beverage$1,836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,836 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,178
Medicare patients
167
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$26,376
JardianceEmpagliflozin13$17,815
XareltoRivaroxaban23$11,585
Levothyroxine Sodium59$1,025
Venlafaxine Hcl ErVenlafaxine Hcl15$984
Atorvastatin Calcium102$841
Albuterol Sulfate HfaAlbuterol Sulfate28$662
Duloxetine Hcl22$647
Amlodipine Besylate79$508
Rosuvastatin Calcium54$424
Metoprolol Succinate33$373
Losartan Potassium46$338
SynthroidLevothyroxine Sodium11$321
Ezetimibe11$288
Montelukast Sodium22$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$120$26,37624 claims
Johnson & JohnsonXarelto$116$11,58523 claims
AbbVieSynthroid$235$32111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →